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In order to gain more insight into mechanisms operating on the haemat-
opoietic activity of the T-cell-derived cytokine, interleukin-17 (IL-17) and target cells




, the influence of a single intravenous injection
of recombinant mouse IL-17 on bone marrow progenitors, further morphologically
recognizable cells and peripheral blood cells was assessed in normal mice up to 72 h




 and NO by
bone marrow cells was determined. Results showed that, in bone marrow, IL-17 did
not affect granulocyte-macrophage (CFU-GM) progenitors, but induced a persistant
increase in the number of morphologically recognizable proliferative granulocytes
(PG) up to 48 h after treatment. The number of immature erythroid (BFU-E) progen-
itors was increased at 48 h, while the number of mature erythroid (CFU-E) progenitors
was decreased up to 48 h. In peripheral blood, white blood cells were increased 6 h
after treatment, mainly because of the increase in the number of lymphocytes. IL-17









 progenitor cells, demonstrated
a slightly enhancing effect of IL-17 on CFU-GM and no influence on BFU-E, suggest-
ing the importance of bone marrow accessory cells and secondary induced cytokines





 IL-17 affects both granulocytic and erythroid lineages, with more mature
haematopoietic progenitors responding first to its action. The opposite effects exerted
on PG and CFU-E found at the same time indicate that IL-17, as a component of a
regulatory network, is able to intervene in mechanisms that shift haematopoiesis from
the erythroid to the granulocytic lineage.
INTRODUCTION
 
The production and activity of haematopoietic cells are both regulated by the interplay of a
number of molecules and key amongst them are the cytokines. The recently identified family of
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interleukin-17 (IL-17)-related cytokines and cognate receptors for these molecules, as a distinct
signalling system highly conserved across vertebrate evolution, has pointed to the important role









. 2004). IL-17 has been characterized as a pro-inflammatory cytokine




 memory T lymphocytes, while the expression of the
IL-17 receptor is ubiquitous in most tissues. Accumulating evidence has confirmed multiple bio-





1998; Schwarzenberger & Kolls 2002). IL-17 can stimulate the production of different kinds of
biologically active molecules, among which are the haematopoietic cytokines and mediators
involved in inflammation. As a part of a complex cytokine network, it appears that IL-17 links
the immune system and haematopoiesis, exhibiting a regulatory function on haematopoiesis via
secretion of both stimulatory and inhibitory cytokines.




, are not completely









 only in the presence of a fibroblast




. 1996). Since these effects were associated with the increased release
of haematopoietic active cytokines, such as granulocyte colony-stimulating factor (G-CSF) and
IL-6 from the fibroblast feeder layer, it was suggested that IL-17 achieved its effect on primitive





delivery of mIL-17 cDNA to the liver, showed the stimulation of haematopoiesis, specifically of
granulopoiesis, in mice with the expansion of committed and immature haematopoietic progen-




. 1998). In a




 the influence of IL-17 on haematopoietic progenitor










. 2001). The observed effects were lineage dependent and related to the progenitors’ stage
of differentiation, as well as being dependent on the physiological /pathological status of the
organism.




 action of IL-17 on constitutive














In order to study the IL-17 target cell range, the effects of a single intravenous (i.v.) administra-
tion of recombinant mouse IL-17 (rmIL-17) on bone marrow granulocyte-macrophage (CFU-
GM) and erythroid (BFU-E and CFU-E) progenitor cell compartments, further morphologically
recognizable cells, as well as peripheral blood haematological parameters were examined at dif-
ferent time intervals after treatment. Evaluation of target cells that first respond to the action of
this T cell-derived cytokine may also help better understanding of the contribution of T cells in
regulation of haematopoiesis and the inflammatory response. At the same time points, the influ-





 and nitric oxide (NO) by bone marrow cells was analysed. Namely, it is well
documented that, within the haematopoietic microenvironment, bone marrow stromal cells are
crucial for providing positive and negative signals for proliferation and differentiation of
haematopoietic cells, and that IL-17 stimulates fibroblasts and stromal cells to release pro-












. 2004). In addition, an effort has been made to
resolve the mode of IL-17 action on progenitor cell compartments, that is to distinguish the




 effects of increasing con-




 progenitor cells were assessed in
the colony formation assays.
 
























The experiments were carried out in normal inbred male CBA mice weighing 20–22 g (Breeding
Facilities of the Institute for Medical Research, Military Medical Academy, Belgrade). The




g of rmIL-17 (R & D Systems, Minneapolis, MN, USA) dissolved in saline
and administered i.v. in a volume of 0.2 ml. Mice were killed 6, 12, 24, 48 and 72 h after treatment.
To distinguish IL-17 mediated effects from the effects caused by the injection procedure itself,
beside non-treated mice, saline-treated mice were used as controls. In each animal, the following
haematological parameters were estimated: in the femoral bone marrow, the number of CFU-
GM-, BFU-E- and CFU-E-derived colonies, the total number of nucleate cells and differential
count of morphologically recognizable cells were performed. In peripheral blood, haematocrit,
the total number and differential count of nucleated cells, the number of erythrocytes and the
percentage of reticulocytes were derived. At the same time points after IL-17 treatment, the




 and NO by bone marrow cells was determined. The experi-





Methylcellulose cultures for CFU-GM and BFU-E were performed using MethoCult GF
M3434 methylcellulose medium with recombinant cytokines (50 ng/ml rmSCF, 10 ng/ml
rmIL-3, 10 ng/ml rhIL-6 and 3 units /ml rhEpo, Stem Cell Technologies, Vancouver, BC, Canada)
following the instructions of the manufacturer, while for CFU-E determination MethoCult

















 for CFU-E were suspended in 1 ml of









 in air. The number of colonies was counted at
day 2 for CFU-E and day 7 for CFU-GM and BFU-E using an inverted microscope.
 
Estimation of morphologically recognizable bone marrow cells
 
On bone marrow cell smears stained by the May–Grunwald–Giemsa procedure, 1000 morpho-
logically differentiated nucleate cells on each smear were observed and divided into the following
compartments: proliferative granulocytes, metamyelocytes, mature granulocytes, monocytes,
lymphocytes, erythroblasts and orthochromatic blasts. Myeloblasts, promyelocytes and myelocytes,
cells capable of replication, constitute the mitotic or proliferative granulocytes compartment
(PG).
 
Estimation of peripheral blood cells
 
Differential counts of nucleated cells were made on 100 counted cells on blood smears stained
by the May–Grunwald–Giemsa procedure. The reticulocytes were stained with brilliant cresyl





To evaluate the influence of rmIL-17 administration on cytokine release and nitrite accumulation









/ml) were prepared from each animal in Dulbecco’s modified Eagle’s medium
 
































C in a humidified atmos-


















concentrations in bone marrow cell-derived conditioned media was performed using ELISA
kits following instructions provided by R & D Systems (Minneapolis, MN, USA). The insulin-
like growth factor-I (IGF-I) levels were determined using radioimmunoassay kits (INEP, Zemun,
Serbia and Montenegro). The sensitivity of these assays enables detection of cytokine concen-








Production of NO by bone marrow cells was determined indirectly by measuring accumulation









l samples of culture supernatants were mixed with equal volumes of 1% sulphani-








. After 10 min at














 haematopoetic progenitor cell population from bone marrow was
obtained using SpinSep Cocktail for Negative Selection from Stem Cell Technologies (Vancouver,
BC, Canada) following the recommendations of the manufacturer. This depletion cocktail
includes the monoclonal antibodies to the following murine cells /cell surface antigens: CD5
(Ly-1), CD45R (B220), CD11b (Mac-1), erythroid cells (TER119), Ly-6G (Gr-1) and neutrophils
(7–4). To assess the influence of IL-17 on the growth of haematopoietic progenitor cell (CFU-




 enriched cell populations (1–5 × 103/ml) were cultured
in the presence of increasing concentrations of IL-17 (0–100 ng/ml) using MethoCult GF
M3434.
Statistical analysis
The comparison between the results of rmIL-17-treated and control, normal, non-treated and
saline-treated mice, was performed by Student’s t-test using the Origin PC Program with the
actual numbers of each investigated parameter. Data were expressed as means ± SEM and
a P-value less than 0.05 was considered to be statistically significant.
RESULTS
In vivo haematopoietic activity of IL-17 was assessed in normal mice after a single intravenous
injection of rmIL-17 by the analysis of cellular and cytokine release changes at different time
intervals (6, 12, 24, 48 and 72 h) after treatment. Because IL-17 mediated biological effects in
vivo could interfere with the response of the organism to stress caused by the injection procedure
itself, obtained results were analysed and compared with two control groups, normal, non-treated
and saline-treated mice, respectively.
Influence of IL-17 on bone marrow progenitor cells
In the bone marrow of investigated mice, the number of CFU-GM-derived colonies was not
significantly affected by either IL-17 or saline treatment at all observed time points and their
numbers oscillated within the values found for the normal mice (Fig. 1a). The estimation of
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Figure 1. In vivo influence of rmIL-17 on femoral (a) CFU-GM, (b) BFU-E and (c) CFU-E-derived colonies growth
in normal mice at different time points after treatment. The data points represent means ± SEM of three to five experi-
ments each performed in duplicate. (––) IL-17-treated mice; (––) saline-treated mice; (– — –) non-treated mice.
Significance at *P < 0.05, **P < 0.01, ***P < 0.001 for IL-17- and saline-treated vs. non-treated mice; and at #P < 0.05,
###P < 0.001 for IL-17-treated vs. saline-treated mice.
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immature erythroid progenitor cells (BFU-E) showed that IL-17 treatment significantly
increased the number of femoral BFU-E-derived colonies 48 h after administration (Fig. 1b), in
comparison with both control groups, normal, non-treated (P < 0.001) and saline-treated mice
(P < 0.05). However, at this time point, saline treatment also induced the increase of BFU-E-
derived colony number, but to a lesser extent than IL-17 treatment. In contrast to the effect on
BFU-E, IL-17 treatment resulted in a significant reduction in the number of mature erythroid
progenitor cells (CFU-E) in comparison with both control groups. As early as 6 h after IL-17
administration, the number of CFU-E-derived colonies was decreased, reaching the minimum at
24 h, while at 72 h their number returned to normal values (Fig. 1c). The number of CFU-E was
not significantly altered by saline treatment, and oscillated within the values found for the
normal, non-treated mice.
Influence of IL-17 on morphologically recognizable bone marrow cells
No significant differences in the bone marrow cellularity were found between IL-17-treated
mice and both control groups during all observed time points. Examination of the bone marrow
morphologically recognizable haematopoietic cells showed that the cells of macrophage, lym-
phocyte and erythroid lineage were not significantly affected by IL-17 treatment (data not shown).
However, IL-17 treatment induced significant alterations in the cells of granulocyte lineage. The
analysis of changes within different granulocytic cell compartments demonstrated a significant
increase in the absolute number of proliferative granulocytes (PG) already 6 h after IL-17
administration, as compared with both control groups of mice (Fig. 2). The persistent increase
in the absolute number of PG was evident up to 48 h after IL-17 injection, while at 72 h their
Figure 2. The effect of a single dose of rmIL-17 on morphologically recognizable proliferative granulocytes (PG) in
normal mice at different time points after treatment. The data points represent means ± SEM of five separate experi-
ments. (––) IL-17 treated mice; (––) saline treated mice; (– — –) non-treated mice. Significance at *P < 0.05,
**P < 0.01, ***P < 0.001 for IL-17- and saline-treated vs. non-treated mice, and at #P < 0.05, ###P < 0.001 for IL-17-
treated vs. saline-treated mice.
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number returned to normal values. Saline treatment did not induce any changes in the number
of PG. At the same time, within post-mitotic granulocyte compartments, no significant alterations
were determined in the number of metamyelocytes and mature granulocytes, by both IL-17 and
saline treatments (data not shown).
Influence of IL-17 on peripheral blood cells
Analysis of haematological parameters in peripheral blood demonstrated that IL-17 induced a
significant increase of the total number of white blood cells (WBC) 6 h after application in com-
parison with both control groups, non-treated (P < 0.001) and saline-treated mice (P < 0.01)
(Table 1). At the same time point, saline treatment also led to some transient increase of WBC,
but to a lesser extent than IL-17 treatment (P < 0.05). Differential counts of nucleated cells showed
that the observed increase of WBC in IL-17 and saline-treated mice was mainly as a result of
the increase in the number of lymphocytes. After 6 h, IL-17 did not induce any statistically sig-
nificant changes in the number of peripheral blood cells in comparison with saline-treated mice,
and their values at 24 h were almost normal. The other investigated parameters (the number of
erythrocytes, the percentage of reticulocytes and haematocrit) were not affected by IL-17 treatment
(data not shown).
Influence of IL-17 on cytokine release and NO production by bone marrow cells
Simultaneously with the assessment of cellular changes, at the same time points after admini-
station, the influence of IL-17 on the production of IL-6, IL-10, IGF-I and IFN-γ, as well as on
nitrite accumulation by bone marrow cells, was determined. In the bone marrow cell-derived
conditioned media of non-treated mice, detectable amounts of IL-6, IL-10, IGF-I and nitrite
were measured, while IFN-γ was below detectable levels (Table 2). IL-17 significantly increased
the release of IL-6, 6 h after administration. Although saline treatment also augmented IL-6
release by bone marrow cells, significantly higher concentrations of IL-6 were found in IL-17-
treated mice than in saline-treated animals. In comparison with constitutive secretion, IL-10
release by bone marrow cells was significantly increased only 6 h after both IL-17 and saline
administration. However, in this case, there were no differences between IL-17-treated and
saline-treated mice. The basal IGF-I release by bone marrow cells was not affected either by IL-
17 or by saline treatment, while the secretion of IFN-γ was below detectable levels in all experi-
mental groups in all tested time points. The estimation of NO production by bone marrow cells
Table 1. The effect of a single dose of rmIL-17 on peripheral blood cells
 
 
Time Group × 109/ l 
WBC GRAN MONO LYMPHO Other cells
N 4.96 ± 0.37 1.65 ± 0.19 0.17 ± 0.02 3.03 ± 0.33 0.11 ± 0.22
6 h IL-17 7.31 ± 0.31***† 1.68 ± 0.13 0.25 ± 0.03 5.19 ± 0.24*** 0.19 ± 0.17
Saline 6.17 ± 0.25* 1.31 ± 0.11 0.20 ± 0.04 4.54 ± 0.24* 0.12 ± 0.32
24 h IL-17 5.16 ± 0.43 1.53 ± 0.17 0.19 ± 0.02 3.43 ± 0.24 0.01 ± 0.09
Saline 4.54 ± 0.40 1.41 ± 0.18 0.18 ± 0.02 2.94 ± 0.25 0.01 ± 0.14
Total number of white blood cells (WBC) and the differential counts of peripheral nucleated cells. GRAN, granulocytes; 
MONO, monocytes; LYMPHO, lymphocytes. Values are expressed as means ± SEM of three separate experiments. 
Significance at *P < 0.05, ***P < 0.001 for IL-17- and saline-treated vs. non-treated mice, and at †P < 0.01 for IL-17-
treated vs. saline-treated mice.
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revealed increased nitrite accumulation also only 6 h after IL-17 treatment in comparison with
the constitutive production, as well as with saline treatment. For all tested molecules, after the
initial rise at 6 h after treatment, a decrease in their concentrations was found and already 24 h
after both IL-17 and saline injection the concentrations of all tested cytokines were approaching
normal (Table 2).
In vitro effects of IL-17 on bone marrow Lin–-enriched colony-forming cells
To resolve the direct from indirect effects of IL-17 on haematopoietic progenitor cells, highly
enriched murine Lin– progenitor cells from bone marrow were cultured in the presence of
increasing concentrations of IL-17. The results revealed a slightly enhanced effect of IL-17 on
the growth of CFU-GM-derived colonies, while the growth of BFU-E derived colonies was not
affected by IL-17 (Fig. 3).




Time Group IL-6 (pg/ml) IL-10 (pg/ml) IFN-γ (pg/ml) IGF-I (pg/ml) NO (µmol)
N 187.9 ± 31.7 52.55 ± 4.9 < 2‡ 3.62 ± 0.7 2.75 ± 0.3
6 h IL-17 470.75 ± 41.3***† 121.12 ± 5.9*** < 2 2.2 ± 0.1 4.94 ± 0.8**†
Saline 310.25 ± 16.7* 142.41 ± 20.6*** < 2 3.23 ± 0.8 3.0 ± 0.4
24 h IL-17 204.4 ± 39.9 78.6 ± 13.1 < 2 3.77 ± 0.8 3.8 ± 0.6
Saline 192.83 ± 65.0 79.5 ± 7.7 < 2 2.15 ± 0.2 2.9 ± 0.8
The cells were obtained from non-treated mice (N) and IL-17- and saline-treated 6 h and 24 h after injection. Cells (5 ×
106/ml) were cultured for 48 h at 37 °C and cell-free supernatants were collected. Values are expressed as means ± SEM.
Significance at *P < 0.05, **P < 0.01, ***P < 0.001 for IL-17- and saline-treated vs. non-treated mice, and at †P < 0.05
for IL-17-treated vs. saline-treated mice. ‡The secretion of IFNγ was below detectable levels.
Figure 3. In vitro influence of increasing concentrations of rmIL-17 on femoral CFU-GM () and BFU-E ()-derived
colonies growth in bone marrow highly enriched Lin– cell fraction obtained from normal mice. The data points represent
means ± SEM of four experiments each performed in duplicate.
© 2004 Blackwell Publishing Ltd, Cell Proliferation, 37, 401–412.
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DISCUSSION
Our previous in vitro study showed that IL-17 increased CFU-GM and BFU-E but reduced CFU-
E-derived colony number in the bone marrow cells, from normal mice (JovciÇ et al. 2001).
Based on these findings, the goal of the current study was to gain more insight into mechanisms
operating on the IL-17 action and heterogeneity of its haematopoietic target cells in vivo. For
this purpose, we used one well-established method for the investigation of the in vivo cytokine
activity, that is its administration as recombinant protein. The results obtained demonstrated that
a single dose of IL-17 elicited a cascade of biological changes in vivo, affecting the haematopoietic
cells from both granulocytic and erythroid lineages, as well as the levels of cytokines released
by bone marrow cells, as early as 6 h after administration.
The measurement of cytokine production by bone marrow cells revealed a rapid increase in
IL-6 and IL-10 levels, as well as elevated nitrite accumulation, 6 h after IL-17 administration.
Elevation of IL-6 and IL-10 in the saline-treated animals, indicates that the injection itself
activated host defence mechanisms known to induce cellular changes and elevation of pro-
inflammatory cytokines during an immediate stress-like response. However, IL-17 led to much
higher release of IL-6 than the saline treatment, and this difference could be ascribed to the effect
of IL-17 itself. This is consistent with the well-known ability of IL-17 to trigger the production
of IL-6 in a variety of cells. As regards IL-10, both IL-17 and saline treatments augmented its
release to the same extent. Concomitant elevation of this anti-inflammatory cytokine in both
groups of animals indicates an effort of the organism to overcome the disturbance caused by the
host defence reaction to the injection procedure itself and change in blood volume. The concen-
trations of elevated mediators decreased afterwards and 24 h after injection were within normal
values. Investigated cytokine profiles of IGF-I and IFN-γ did not change during the whole exam-
ined period. The lack of more significant changes in cytokine levels could be also as a result of
the experimental procedure used, as the production of cytokines by bone marrow cells was ana-
lysed following 48-h incubation in vitro. The possibility that the in vitro manipulation caused
alterations in bone marrow cells’ ability to release cytokines could not be excluded. Cytokine
levels in peripheral blood serum and/or bone marrow extracts should be further analysed in
order to provide better insight in the consequences of IL-17 in vivo action.
Assessment of the IL-17-induced changes within different compartments of granulocytic
lineage demonstrated that one injection of IL-17 did not significantly affect femoral CFU-GM,
but induced considerable increase in morphologically recognizable neutrophil precursors,
proliferative granulocytes (PG). The lack of IL-17 effect on CFU-GM was unexpected and was
contradictory to previously reported in vivo IL-17 stimulation of granulopoiesis which was
accompanied by the expansion of haematopoietic progenitors and neutrophilia (Schwarzenberger
et al. 1998). Our experimental approach was under different conditions from those obtained by
the usage of the recombinant adenovirus expression system where effective production of IL-17
was provided. One possible explanation is that the dose of IL-17 applied was not sufficient to
alter the CFU-GM compartment, as our previous data in vitro showed also the requirement of
relatively high concentrations of IL-17 for stimulation of CFU-GM growth (JovciÇ et al. 2001).
Although our additional experiments performed in vitro with the highly enriched Lin– bone
marrow progenitor cell fraction revealed a slightly enhancing effect of IL-17 on the CFU-GM
growth, at present it is difficult to draw any conclusion about the mode of IL-17 mediated effect
on the CFU-GM. Further investigations are necessary to determine the precise mechanisms and
regulatory steps of IL-17 stimulated granulopoiesis in vivo, especially at the level of progenitor
cells. However, the most obvious in vivo response of granulocytic cells to IL-17 administration
© 2004 Blackwell Publishing Ltd, Cell Proliferation, 37, 401–412.
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was observed at the level of PG. A significant and continuous increase in the number of cells in
this compartment was evident from 6 h after IL-17 injection onward. To our knowledge, this is
the first demonstration of the effect exerted by IL-17 on morphologically recognizable prolifer-
ative granulocytes. This finding may be of importance in understanding the mechanisms by which
IL-17 is involved in the regulation of granulopoiesis and the inflammatory response, bearing in
mind that neutrophils are the first host defensive cells to be recruited to the site of inflammation.
In order to meet the emergency demand for a massive number of granulocytes, it cannot be ruled
out that the most rapid and increased production of granulocytes is provided via regulator(s) able
to act on the quantitatively largest granulocytic cell compartment capable of proliferating, that
is PG. Thus, one can suppose that IL-17, as mediator and/or modulator of the host defence
responses, signalling through its widely expressed cell surface receptors, might participate in the
stimulation of granulopoiesis acting at the level of PG, either directly or through enhanced secre-
tion of other cytokines that stimulate granulopoiesis. At the moment it is difficult to distinguish
between these two possibilities, particularly in vivo. IL-17 has been shown to induce G-CSF pro-
duction (Fossiez et al. 1996; Schwarzenberger et al. 1998) and, as for the direct effects of IL-17
on haematopoietic cells, there is little evidence except that IL-17 can activate various members
of the JAK/STAT pathway in human monocytic leukaemia cells (Subramaniam et al. 1999). The
absence of significant changes within post-mitotic granulocyte compartments in the bone
marrow indicates that the dose of IL-17 used was insufficient to increase the production of more
mature cells and/or that the mechanisms towards restoring the disturbed homeostasis were acti-
vated as predominant, as demands for the excess number of granulocytes did not exist. The same
was true for the number of peripheral blood granulocytes. Namely, in peripheral blood, IL-17
treatment increased the number of WBC 6 h after administration – interestingly, mainly as a
result of the increase in the number of lymphocytes. Schwarzenberger et al. (1998) also reported
that IL-17 in vivo can mediate increase in the number of peripheral blood lymphocytes.
While the effects of IL-17 on granulopoiesis have been intensively investigated, the effects
of IL-17 on erythropoiesis have received relatively scant attention. Our results demonstrated the
profound in vivo effects of IL-17 on the erythroid progenitor cell compartments. In accordance
with its pleiotropic nature, as well as our in vitro data (JovciÇ et al. 2001), IL-17 exerted opposite
effects on erythroid progenitors; stimulatory on immature progenitors, BFU-E and inhibitory on
mature progenitors, CFU-E. The number of femoral BFU-E increased significantly 48 h after IL-
17 treatment in comparison with both normal and saline-injected animals. Because saline treatment
also temporarily increased BFU-E, the observed IL-17 effect on BFU-E was, in a part, non-specific
and interfered with the action of secondary mediators elevated in response to the stress caused by
the injection and, at least partly, was specific to IL-17. The effect of IL-17 on BFU-E was probably
mediated through its ability to induce the release of secondary cytokines, particularly IL-6. In favour
of this assumption is the fact that in IL-17-treated mice the levels of IL-6 produced by bone marrow
cells were significantly higher than in controls. It is well known that IL-6 exhibits stimulatory
effects on haematopoiesis, specifically erythropoiesis (Kishimoto 1989). Moreover, it was demon-
strated that in vivo IL-6 can increase the number of femoral BFU-E in normal mice (Pojda
& Tsuboi 1990). Also, it cannot be excluded that the reduced number of CFU-E which persisted
up to 48 h after IL-17 administration was a signal for the more extensive BFU-E proliferation and
differentiation observed in IL-17-treated mice, in order to restore the dynamic equlibrium between
BFU-E and CFU-E. In any case, the results suggest that the observed in vivo effects of IL-17 on
BFU-E were predominantly indirect via secondarily induced cytokines. This is additionally supported
with our data obtained in vitro. Namely, in our previous experiments, when we used unseparated
bone marrow cells, in order to mimic in vivo conditions and to provide the presence of accessory
cells, IL-17 enhanced the growth of BFU-E-derived colonies, and simultaneously augmented the
© 2004 Blackwell Publishing Ltd, Cell Proliferation, 37, 401–412.
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release of IL-6. In contrast to these data, as presented here, no in vitro effect of IL-17 was
observed on the formation of BFU-E colonies by highly enriched Lin– bone marrow cells, sug-
gesting the necessity of the presence of accessory cells for IL-17 mediated effects on BFU-E.
Concerning the in vivo effect of IL-17 on femoral CFU-E, the obtained results again confirmed
our previous in vitro finding that IL-17 induces a decrease in their number. At present the mech-
anism(s) by which IL-17 suppressed the number of CFU-E is unknown. However, increased nitrite
accumulation determined only in IL-17-treated animals, led us to assume that the suppressing effect
of IL-17 on CFU-E might be, at least partly, mediated by NO generation. It has been previously reported
that at low concentrations NO can actually enhance CFU-GM colony growth, while inhibiting
erythroid cell (CFU-E) growth from human bone marrow CD34+ cells (Shami & Weinberg 1996).
In contrast, IL-17 has been shown to induce NO production in a variety of cells (MiljkoviÇ &
TrajkoviÇ 2004). In support of this assumption, that the reducing effect of IL-17 on CFU-E might
be mediated by NO, are our in vitro results that IL-17 can stimulate low level production of NO
in murine bone marrow cells and that iNOS inhibitors can reverse the in vitro CFU-E suppression
by IL-17 in a dose-dependent manner (Bugarski et al. 2004). However, because an increased
production of NO by bone marrow cells was not detected after 6 h post-IL-17 treatment, the
possibility that other negative factor(s) and mechanisms are involved in the prolonged IL-17
reducing effect on CFU-E could not be excluded. In any case, this in vivo IL-17 mediated inhibitory
effect on CFU-E might be of special importance in view of the role of this cytokine in the inflam-
matory response of organism. Namely, one can suppose that, during inflammation, signalling
pathways activated by IL-17 might selectively switch bone marrow cell production from the
erythroid to the granulocyte lineage by attenuating CFU-E proliferation and/or differentiation.
Taken together, our results suggest that IL-17, as a cross-talk cytokine between the immune and
haematopoietic systems, can influence haematopoiesis in vivo at different levels, as well as the
release of secondary mediators with haematopoietic effects. The results are basically in agreement
with the hypothesis that IL-17 is involved in the regulation of granulopoiesis and may play an
important role in the initiation and/or maintenance of the inflammatory response. Evaluation of
target cell range pointed to the heterogeneity of haematopoietic cells affected by IL-17. The most
profound and rapid effects of IL-17 were observed on PG and CFU-E, suggesting that, in vivo,
in the bone marrow more mature haematopoietic progenitors are the first to respond to its action.
Additionally, the opposite effects exerted on PG and CFU-E imply that IL-17 may be one of the key
cytokines that coordinate and control haematopoiesis, as in this way IL-17 can enable the switch
in cell production from the erythroid to the granulocyte lineage during inflammation or infection
when enhanced defences are required. The capacity of IL-17 to significantly stimulate proliferation
of PG after a single application indicates its therapeutical potential and encourages further inves-
tigation in vivo towards development of new modalities in therapy of patients with compromised
granulopoiesis. Novel experimental approaches are required, especially suitable animal experimental
models with disturbed haematopoiesis, and also varying dose schedules. Namely, the requirements
for and the effects of cytokines are not equal during constitutive and inducible haematopoiesis
and, according to our studies, cytokines express only some of their potential effects in the steady
state, either on haematopoietic cells or cytokine release (JovciÇ et al. 1996; Bugarski et al. 2000).
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